Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.66 |
| ▸ | FASN | P49327 | 1/20 | 0.60 |
| ▸ | ESR1 | P03372 | 3/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.59 |
| ▸ | CSF1R | P07333 | 3/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.51 |
| ▸ | AR | P10275 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 8/20 | 0.48 |
| ▸ | PDE9A | O76083 | 1/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29031851 | 0.81 | FASN (0.56) | MEN1KMT2AFASNESR1ESR2 | |
| SCHEMBL30472347 | 0.81 | FASN (0.56) | MEN1KMT2AFASNESR1ESR2 | |
| SCHEMBL18552154 | 0.78 | ESR1 (0.69) | ESR1ESR2PTGS2 | |
| SCHEMBL18552201 | 0.78 | ESR1 (0.69) | ESR1ESR2PTGS2 | |
| SCHEMBL19967788 | 0.78 | MEN1 (0.57) | MEN1KMT2AFASNCSF1RCYP19A1 | |
| SCHEMBL11354470 | 0.77 | HTR6 (0.55) | MEN1KMT2AFASNCYP19A1 | |
| SCHEMBL18610257 | 0.77 | ESR1 (0.73) | ESR1ESR2PTGS2 | |
| SCHEMBL27902506 | 0.77 | ESR1 (0.67) | ESR1ESR2CYP19A1PTGS2 | |
| SCHEMBL30480932 | 0.76 | CHUK (0.63) | MEN1KMT2AFASNCYP19A1AR | |
| SCHEMBL1247669 | 0.76 | CHUK (0.63) | MEN1KMT2AFASNCYP19A1AR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207732-A1 | AZAINDOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-08-25 | — | — | US | claimed |
| US-20110207732-A1 | AZAINDOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-08-25 | — | — | US | disclosed |
| US-20110207732-A1 | AZAINDOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-08-25 | — | — | US | disclosed |
| WO-2010046013-A1 | AZAINDOLE DERIVATIVE | MERCK PATENT GMBH (DE) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207732-A1 | AZAINDOLE DERIVATIVES | AZI2, ABL1, RET | MEN1 128/4885KMT2A 238/4885FASN 4731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.